BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
April 29, 2020 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority
April 03, 2020 06:58 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer
April 01, 2020 09:00 ET
|
BrainStorm Cell Therapeutics Inc.
International Pharmaceutical Veteran to Lead Global Business and Commercial Development Ralph Kern, MD, MHSc, Promoted to President NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell...
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors
March 31, 2020 04:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced the...
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
March 16, 2020 03:00 ET
|
BrainStorm Cell Therapeutics Inc.
Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones Call Time: Wednesday, March...
BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share
March 06, 2020 09:25 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has...
Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
February 27, 2020 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019
February 18, 2020 07:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces...
BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference
February 17, 2020 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 17, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
February 11, 2020 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...